Background: Obesity is an increasing health problem and surgery seems to be the only treatment effective in achieving weight loss without relapse. Among bariatric techniques, many differences exist in terms of weight loss and resolution of comorbidities. Up to now, there are no prospective studies comparing long-term effects of malabsorptive vs restrictive techniques. Objective: In this study, cardiometabolic risk factors and body composition changes after malabsorptive biliointestinal bypass (BIBP) and restrictive laparoscopic adjustable gastric banding (LAGB) were compared during a 4-year follow-up. Design: Prospective, case-control and cohort study. Patients: In all, 80 obese subjects, matched for weight and age. Altogether, 40 patients underwent BIBP and 40 underwent LAGB. Measurements: Weight, body composition, fasting and post-loading plasma glucose and insulin, homeostatic model assessment index (HOMA-I), lipid profile, blood pressure (BP), erythrocyte sedimentation rate and fibrinogen were monitored at baseline, 12 and 48 months. Results: At 12 months after surgery, a significant reduction in body mass index, total fat mass (FM), trunk FM (trFM), trFM/legs FM (lFM) ratio (trFM/lFM), triglycerides, BP and inflammation markers was observed in both groups. BIBP patients showed a significant reduction in total cholesterol (Tot-C), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), whereas the LAGB group showed a significant increase of HDL-C. A further improvement of all the parameters evaluated was seen in the BIBP group at 48 months after surgery. Conclusions: Both bariatric procedures exerted positive effects on cardiometabolic risk factors and on weight loss in the population studied, but on the long-term period, HOMA-I, Tot-C/HDL-C ratio and body composition improvements were more evident after BIBP. We conclude that malabsorptive BIBP seems to be more effective than LAGB in treating visceral obesity and its metabolic complications
Introduction
More than half of the European population is overweight and up to 30% is obese. 1 Obesity is associated with type 2 diabetes mellitus, dyslipidemia, hypertension and coronary heart disease (CHD). 2 The epidemic diffusion has led to the development of therapies aimed at weight loss. The longterm effects of diet, exercise and medical therapy are relatively poor. 3 The rate of bariatric surgery procedures are increasing sharply and to date it is the only option resulting in substantial and durable weight loss. 4 Several epidemiological evidences indicate that the prevalence of comorbidities decreases with weight reduction. 5 The effectiveness of bariatric surgery on weight loss and on cardiometabolic related risk factors is out of doubt. 6 The bariatric surgery is reported to be very effective in obtaining up to 60% loss of the excess body weight with improvement in the comorbidities. 7 After bariatric treatment, resolution of hyperglycemia in a very high percentage of cases is reported; 8, 9 the predicted risk of CHD decreases to rates lower than age-and gender-adjusted estimates for the general population, suggesting that weight loss may be a preventive shunting to reduce myocardial infarction and death rate in obese subjects. 10 Hyperlipidemia is strongly improved by some surgical procedures. 11 Considering the very low postoperative mortality, 12 surgery seems to represent a valid approach to treat obesity and related diseases. The National Institute of Health panel set general guidelines for bariatric surgery for patients with body mass index (BMI) X40 or X35 kg m -2 if comorbidities are present. 13 However, there are not yet clear indications regarding the choice between malabsorptive or restrictive surgery and, up to now, there is a lack of prospective studies that are able to compare weight loss, body composition and cardiovascular outcomes among different bariatric techniques on long-term period.
Biliointestinal bypass (BIBP) is a pure malabsorptive procedure and laparoscopic adjustable gastric banding (LAGB) is a pure restrictive one; both are reversible and show a very low rate of complications. In this study, we compared long-term effects of BIBP and of LAGB on several cardiometabolic risk factors and on body composition parameters.
Methods

Patients' recruitment
Initially, patients desiring surgical intervention for the treatment of obesity were referred to the University Clinic experienced in the care of obese and bariatric patients to determine the patients' eligibility for surgery on the basis of the international guidelines. 13 Only patients with BMI 440 kg m -2 or with BMI 435 kg m -2 with comorbidities, in whom all appropriate nonsurgical measures failed to achieve or maintain adequate weight loss for at least 6 months, without any psychiatric problem and/or drug or alcohol addiction were admitted to surgery. Psychiatric problems were evaluated on the basis of tests such as eating disorder examination, body dismorphic disorder examination and other tests related to general psychopathology. 14 Exclusion criteria were secondary causes of obesity, pregnancy, antipsychotic medication, severe altered selfbody image and nonrealistic expectations about weight reduction. BIBP was chosen in those conditions in which restrictive bariatric surgery seemed not to be suitable: binge eating disorder, grazing and night eating, and emotional eating. If a subject was eligible, an operation was scheduled after an informed consent was obtained. The local human ethics committee approved the study.
All surgical procedures were conducted from 1999 to 2005 in the University Surgical Department. All patient assessments and outpatient treatments were conducted in the University Clinic Medical Department.
The total number of patients undergoing bariatric surgery during the recruitment period was 152, of whom 80 were eligible for our study on the basis of the following inclusion criteria: age (20-55 years), weight (o150 kg) because of dualenergy X-ray absorption (DXA) technical limitation, race (Caucasian), the absence of any psychopathology except for eating disorders, motivation, proximity to the hospital, job type and acceptance of follow-up length (Figure 1 ) who were treated by LAGB.
None of the patients recruited for the study had suffered from a cardiovascular accident in the past.
Metformin was used as glucose-lowering drug, fenofibrate was used as lipid-lowering compound, and ace inhibitors and sartans as blood pressure (BP)-lowering agents. Insulin was never used in both groups. Lipid-, glucose-and BP-lowering agents were allowed until necessary, according to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines. 15 
Assessment
Data were collected before and 12 and 48 months after surgery. A multidisciplinary team (an internist, a cardiologist, an endocrinologist, a gastroenterologist, a psychiatrist, a surgeon, a nutritionist) met with each patient every 6 months and decided the overall medical treatment. The schedule of follow-up for band fills was every month for the first 6 months after surgery, then every 6 months. The nutritionist and the surgeon of the team determined whether the band should be adjusted. The adherence to follow-up was excellent. Educational materials were provided to the patients and preoperative educational sessions were performed for each patient of both groups regarding the risks and benefits of bariatric surgery and procedural options. Nutrition and meal-planning guidance were provided to the patient and family before bariatric surgery and during the postoperative hospital course and reinforced during outpatient visits. The acute postoperative diets (first and second day) were similar in both groups and consisted of noncarbonated clear liquids with no calories, no sugar and no caffeine. A consultation with a nutritionist was performed to suggest the right diet for each group: BIBP patients were suggested to initially eat the tolerated amount of protein and to increase it progressively and LAGB patients to adhere to a standardized protocol for meal progression. 16 Blood samples were collected and BP was measured in the morning (usually between 0800 and 0900) after an overnight fast. Body composition was evaluated by DXA analysis (Hologic Inc, Bedford, MA, USA, QDR 4500W, S/N 47168) with coefficient of variation of o1% for bone density and o1.5% for fat mass (FM). Specific delimiters for regional analysis were determined by the standard software supplied by Hologic (QDR 4500W (S/N 47168 VER. 11.2). With the use of specific anatomical landmarks, regions of the head, trunk, arms and legs were distinguished. In particular, the legs and arms were defined as the soft tissue extending from a line drawn through and perpendicular to the axis of the femoral neck and angled with the pelvic brim to the phalange tips and the soft tissue extending from the center of the arm socket to the phalange tips, respectively. The trunk was defined as the area of the body that extends below the collarbone and above the ideal line joining the iliac crests. Scans were performed according to the manufacturer's instructions with subjects in the supine position. Before each scanning session, the Hologic QDR 4500W was calibrated according to the standard procedures recommended by the manufacturer. [19] [20] [21] [22] [23] [24] BP was measured by a mercury sphygmomanometer (Riva-Rocci System, ERKA, Chemnitz, Germany).
After surgery, we recommended the following supplementations for BIBP patients: chewable multivitamin with minerals two times per day, iron supplement 20 mg per day, vitamin B12 350 mg per day, folic acid 5 mg per day 
Eligible n= 80
Not eligible n = 72
Admitted to bariatric surgery n=152
Not admitted to bariatric surgery
Figure 1 Selection flowchart (see test).
Bariatric surgery and cardiometabolic risk factors C Lubrano et al (in some cases intramuscularly), vitamin A 5000 IU per day, vitamin D 0.5 mg per day, vitamin E 400 IU per day and vitamin K 1 mg per day. In case of LAGB patients, we suggested chewable multivitamin with minerals two times per day and vitamin D 0.5 mg per day.
Description of surgical interventions
The same set of surgeons performed both BIBP and LAGB interventions. BIBP is a purely malabsorptive technique in which the small bowel is almost completely excluded from food transit (Figure 2a ). The blind intestinal loop is anastomosed to gallbladder. [25] [26] [27] [28] The cholecystojejunal anastomosis facilitates bile transit into the excluded loop and reduces bile salts malabsorption. 29 The jejunum was transected 30 cm distal to
Treitz and a side-to-side anastomosis 12-18 cm of length between proximal jejunum and terminal ileum was created.
On the excluded ileum an anti-reflux valve system was handsutured. BIBP affects the enterohepatic axis function by diverting food away from the proximal gastrointestinal tract and by delivering incompletely digested nutrients to the ileum. BIBP can be reversed to normal with the exception of a cholecystectomy. In all, 26 laparotomic and 14 laparoscopic BIBP were performed. LAGB is a restrictive technique performed to obtain a 15-20 ml gastric pouch 30 ( Figure 2b ).
This procedure involves laparoscopic placement of an adjustable gastric band around the upper stomach. A balloon within the band is connected to a subcutaneous port that can be accessed percutaneously to adjust band circumference on the basis of patient's rate of weight loss and of gastrointestinal symptoms. All patients in the LAGB group were operated using the perigastric technique with the 9.75-cm Lap-Band System (INAMED Health, Santa Barbara, CA, USA).
Adverse events
All patients in the study were questioned about the occurrence of adverse events at each consultation and the physicians recorded the results on the data sheets.
Statistical analysis
Results are compared by one-way analysis of variance for repeated measures at a two-tailed a-level of 0.05. Spearman's correlation test was used to measure a linear association between continuous variables. To evaluate the magnitude of treatments effect independent from sample size, we used Cohen's d for each paired values. Statistical analysis was performed by STATISTICA software version 6.1 (Stat Soft, Inc, Tulsa, OK, USA).
Role of the funding source
The study was funded by Sapienza University. The laparoscopic adjustable gastric bands (INAMED Health) were provided by the manufacturers. These sources had no role in the design, conduct, analysis or reporting of the study, or in the decision to submit the paper for publication. Bariatric surgery and cardiometabolic risk factors C Lubrano et al
Results
Baseline characteristics of participants Patients were matched for age and weight. All the parameters evaluated before surgery did not significantly differ between the groups (Table 1) . (Table 3) .
Follow-up results
Body composition At 1 year after surgery, a significant reduction in %FM, of percent trunk FM (%trFM) and of trFM was observed in the BIBP group (Po0.001), and a further significant improvement was seen after 4 years (P ¼ 0.005 vs 1 year).
In LAGB patients, a conspicuous reduction in %FM (P ¼ 0.022), of %trFM (P ¼ 0.014) and of trFM (Po0.001) was evident at 1 year, but there was no progression over time; in fact, between 1 and 4 years these parameters did not vary (%FM, P ¼ 0.937; %trFM, P ¼ 0.698; trFM, P ¼ 0.189). In both groups, a significant reduction of trFM ( Figure 3a) and of trFM/legs FM (lFM) ratio (Figure 3b) was observed during the first 1 year, but the malabsorptive procedure was more effective in ameliorating body composition over time. At 4 years, LAGB patients showed less percent fat free mass (%FFM) than BIBP ones (Po0.001). Total body and lumbar bone mineral density remained unchanged after both procedures.
Blood pressure
In BIBP patients, systolic BP values were significantly reduced after 1 year (P ¼ 0.002) and unchanged after 4 years (Po0.001 vs baseline, P ¼ 0.594 vs 1 year), whereas diastolic BP was significantly decreased only at 4 years (Po0.001 vs baseline). Before surgery, there were 29 hypertensive patients and at the end of follow-up only 10 subjects remained hypertensive (65.6% resolution).
At baseline, 32 out of 40 (80%) LAGB patients were hypertensive. At 1 year systolic and diastolic BP were significantly reduced (Po0.001). However, after 4 years systolic BP was found to be significantly increased with respect to 1 year values (P ¼ 0.011 vs 1 year) and diastolic BP values did not vary (P ¼ 0.885). At the end of follow-up period, 16 patients were still hypertensive (50% resolution) ( Table 3 ).
Lipid profile
In BIBP patients, a marked and progressive reduction in Tot-C and LDL-C (Po0.001) was seen; a significant HDL-C reduction was observed only at 1 year (Po0.001), not substantially changed at 48 months (P ¼ 0.392 vs 1 year) (Figures 4a and b) . In the LAGB group, a significant HDL-C increase (P ¼ 0.022) was seen only at 1 year. No modifications of Tot-C and LDL-C were documented at all time intervals. Tot-C/HDL-C ratio decreased significantly in both groups Bariatric surgery and cardiometabolic risk factors C Lubrano et al (Po0.001), but after 4 years, BIBP patients showed greater Tot-C/HDL-C reduction than LAGB ones (Po0.001) (Figure 4c ). Triglycerides concentrations decreased significantly and progressively in both groups.
Glyco-insulinemic profile
Before surgery, 32.5% of BIBP patients and 45% of LAGB patients showed altered glucose metabolism: 15% of BIBP and 7.5% of LAGB patients were diabetics, 7.5% of BIBP and 10% of LAGB patients had impaired glucose tolerance, and 10% of BIBP and 20% of LAGB patients had impaired fasting glucose ( ; P ¼ 0.004 vs baseline, P ¼ 0.156 vs 1 year). After 1 year, fasting insulinemia and HOMA-I decreased significantly reaching near normal values (Po0.001) and remained unchanged until 48 months (P ¼ 0.206 and P ¼ 0.190 vs 1 year, respectively). (Figure 5a ). The same pattern was observed for post-loading insulin and post-loading glycemia: at 48 months, these parameters were reduced to 22.3 mUI ml
À1
(95% CI 9.6-34.9 mUI ml À1 ) and to 82.2 mg per 100 ml (95% CI 77.3-87.0 mg dl À1 ) (Po0.001 vs baseline). At the end of follow-up, only one patient, previously diabetic, was impaired fasting glucose (92.3% resolution) ( Table 3) . 
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In the LAGB group, FPG at all time intervals were not significantly reduced (P ¼ 0.111 vs 1 year; P ¼ 0.070 vs 4 years) and fasting insulin decreased only at 4 years (P ¼ 0.363 vs 1 year; P ¼ 0.023 vs 4 years). HOMA-I never improved (P ¼ 0.207 at baseline vs 1 year; P ¼ 0.071 at baseline vs 4 years) (Figure 5a ). After 4 years, post-loading glucose and insulin were significantly decreased compared with baseline (Po0.001). At the end of follow-up, only two patients were diabetic, one had impaired glucose tolerance and one had impaired fasting glucose (77.8% resolution) ( Table 3) . A strong linear inverse correlation between trFM and HOMA-I for all patients at every time intervals was demonstrated (r ¼ 0.49367; Po0.001) as shown in Figure 5b .
Inflammatory parameters
In BIBP patients, plasmatic fibrinogen decreased slowly (P ¼ 0.268 at baseline vs 1 year; at 4 years P ¼ 0.002 vs baseline, P ¼ 0.022 vs 1 year). The same pattern was observed for erythrocyte sedimentation rate.
LAGB patients showed a slightly more pronounced fibrinogen reduction (P ¼ 0.194 at baseline vs 1 year; Po0.001 at baseline vs 4 years, Po0.001 1 year vs 4 years).
Adverse events
There was no mortality after both surgical interventions. BIBP patients were hospitalized for about 7 days. There were two patients with pulmonary embolism (pharmacologically treated) and other two with stomal bleeding. It was Bariatric surgery and cardiometabolic risk factors C Lubrano et al transiently observed severe diarrhea with electrolyte imbalance (15%) and anal problems (62.5%), such as inflammation, hemorrhoids and anal fissures which disappeared when the womb stabilized within 3 months from surgery. One patient had gallstones. Patients who did not consume adequate liquids and did not avoid oxalate-rich food had oxalic nephrolithiasis (5%). No patients had liver or kidney failure. Bacterial overgrowth was evident in 15% of patients. All these adverse events did not require further hospitalization. We observed laparocele in 5 out of 26 laparotomic BIBP (19.2%). LAGB patients were hospitalized for about 3 days. 80% patients showed transient nausea and vomiting. One patient experienced band erosion, 15% esophagitis, 5% infection and 5% pouch dilation. Additional hospitalization was necessary for three patients: one had band removal at the 46th month for pouch dilation; other two patients needed band replacement because of band erosion and pouch dilation. The other side effects reported for LAGB patients were managed noninvasively. 31 
Discussion
The use of obesity surgery increased dramatically during the last decade. 32 Bariatric treatments showed to give greater benefits in terms of weight reduction and of diabetes resolution compared with medical therapies 33, 34 and to strongly reduce CHD risk 10 and overall mortality. [35] [36] [37] On long-term period, there are no trials comparing matched patients treated by malabsorptive and by restrictive procedures. The selection criteria for different bariatric techniques are not well defined and are usually based on psychiatric statement, on surgical risks and on initial body weight.
BIBP is a pure malabsorptive bariatric technique routinely performed in many surgical centers in Italy. It is a safe and efficacious procedure: weight loss is satisfactory in 93% of operated patients; mortality rate is 0.4% and reversal rate is about 2.5%; it is completely reversible with the exception of a cholecystectomy and is the least invasive as possible with respect to the anatomy and physiology of the gastrointestinal tract. 28 In fact, BIBP, unlike other malabsorptive techniques such as biliopancreatic diversion, is able to maintain the contact between pancreatic enzymes, bile salts and food, and the absorption of calcium and mineral salts in the duodenum and jejunum; the blind loop, a major problem in jejenoileal bypass, is anastomized to the gallbladder to counteract bacterial overgrowth and to increase the enterohepatic circulation of bile acids and cholesterol.
In this study, we showed that FM loss, FM distribution and cardiometabolic risk factors improvement can vary significantly between malabsorptive and restrictive procedures and these differences should be considered to define the criteria for the choice of bariatric technique.
If bariatric surgery is aimed only at reducing BMI, then both procedures seem to be effective after the 4-year followup, although our data clearly demonstrate that weight loss is significantly greater in the BIBP group than in the LAGB one. However, if the goal of this type of surgery is also to treat visceral adiposity and comorbid conditions, then BIBP seems to be the better treatment option. In fact, data regarding measures of body composition clearly demonstrate the pivotal role of this malabsorptive procedure in ameliorating body fat distribution and concomitant metabolic derangements.
According to literature, we reported that FM and %FM progressively decreased in both group until 1 year. 38 Later, LAGB patients did not show any further FM reduction, whereas BIBP group continued to loss FM. It is well known that the amount of visceral fat is strictly related to development of cardiovascular and of diabetic complications. 39 TrFM evaluated by DXA can be considered as a marker of visceral adiposity like waist circumference. 40, 41 The determination of trFM/lFM ratio is a validated marker of insulin resistance. 23, 24 Furthermore, evaluation of trFM/ lFM ratio takes into account the subcutaneous fat and Bariatric surgery and cardiometabolic risk factors C Lubrano et al characterizes a more metabolically benign phenotype of obesity. 42 It is noteworthy that BIBP patients showed more pronounced reduction of trFM and of trFM/lFM than LAGB at all time intervals. It is known that patients who experienced great weight loss after bariatric surgery but remain still obese show a significant reduction in cardiometabolic risks if significant visceral fat is lost. In both groups, bone mineral density remained unchanged, probably for vitamin D supplementation, and a progressive increase of percent fat free mass was observed. However, at the end of follow-up, LAGB patients had less muscle mass then BIBP ones. Maintenance of fat free mass of particular interest when large amounts of body weight are lost in order to preserve skeletal integrity, muscle tropism and energy expenditure. BIBP and LAGB can differently influence cardiometabolic risk factors and a higher number of dyslipidemic, diabetic and hypertensive patients could be cured if they had undergone BIBP. Both techniques were able to induce similar modifications of triglyceride levels. Regarding cholesterol homeostasis, BIBP led to a marked reduction in Tot-C, HDL-C and LDL-C reaching LDL-C therapeutic target because of iatrogenic malabsorption of bile components, as previously reported. 43 On the contrary, in the LAGB group HDL-C increased, in agreement with other studies. 11,44 At 4 years, however, in BIBP group a significantly more pronounced reduction of Tot-C/HDL-C ratio was seen. It is well established that serum Tot-C, LDL-C, low-level HDL-C and calculated indices such as Tot-C/HDL-C ratio are strongly predictive of cardiovascular events. Among these, Tot-C/ HDL-C ratio and LDL-C represent the most powerful predictors of CHD; 45 so, again, BIBP seems to achieve better results.
In both groups, glyco-insulinemic parameters improved significantly until 12 months; after this time, only BIBP patients continued to ameliorate obtaining near normal values of HOMA-I. On long term, post-bariatric patients are likely to retain a certain degree of insulin resistance if their BMI is still in the overweight or obese range. Malabsorptive procedures seem to improve insulin sensitivity beyond the effect of weight loss. [46] [47] [48] In agreement with these findings, we report that after 4 years altered glucose metabolism was present in 22.2% of LAGB patients and only in 7.7% of BIBP ones. These results were not unexpected considering the highly significant linear correlation between trFM and HOMA-I in our patients. The improvement of insulin sensitivity and glucose metabolism may be due to the more evident reduction of trFM in BIBP patients and possibly to the modified pattern of incretins secretion in malabsorptive surgery. 8, 34, 49, 50 Finally, both surgical interventions were able to reduce systolic and diastolic BP values along with BMI. However, BIBP produced better results in BP control with hypertension resolution rate of 65.6% against 50% in the LAGB group.
Abdominal obesity is closely associated with low-grade inflammation that characterizes a further risk for CHD. 51, 52 In our study, both surgical procedures were able to reduce fibrinogen and erythrocyte sedimentation rate with slightly better results in the LAGB group.
Several limitations of our study need to be mentioned. First, we performed a follow-up of only 4 years to allow a complete collection of data. Second, we evaluated only patients who weighed between 100 and 150 kg for technical limitations (maximum weight allowed by DXA). Third, we did not have measurements of waist circumference because at baseline some patients missing for this parameter. However, the evaluation of trFM by DXA seems to be a suitable alternative.
In conclusion, BIBP seems to be more effective than LAGB in treating visceral obesity. Our data consistently show greater reduction in BMI and of trFM and a better resolution rate of comorbidities in BIBP patients. LAGB patients showed significant improvements in HDL-C and fibrinogen levels, factors known to cooperate in determining cardiovascular risk. At the end of follow-up period, effect sizes measured by Cohen's d indicated medium (0.84d40.5) to strong effects (d40.9) of BIBP on excess body weight loss (kg), percent of excess body weight loss, body composition, FM distribution, lipid profile and glucose metabolism.
Both procedures had acceptable morbidity. Early complications were more commonly observed in BIBP group but reoperations were more frequent in the LAGB group. However, the benefits of the malabsorptive technique (greater weight loss, better metabolic outcomes) seem able to outweigh the lower rates of early complications of restrictive one. Our study is still ongoing and the gaps between BIBP and the LAGB groups in terms of body weight reduction and of cardiometabolic risk factors seem to be maintained over the time. Further studies are needed to evaluate the functional and morphological effects of the modified lipid profile and, in particular, of the HDL-C changes on cardiovascular system in BIBP and LAGB patients.
